1395048-49-3

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC50=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC50s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM[1].

M-110 is a highly isoform-selective, cell permeable and potent ATP-competitive inhibitor of the PIM kinase family that prefers PIM-3. M-110 is an inhibitor of Wnt/β-catenin signaling that act downstream of the symb-catenin destruction complex to inhibit both Wnt-induced and cancer associated constitutive Wnt signaling via destabilization of β-catenin. The compound chelates iron in vitro and in intact cells. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM, with no activity on normal human peripheral blood mononuclear cells up to 40 μM.

Store at -20°C

[1] Chang M, et al.PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.Mol?Cancer?Ther.?2010 Sep;9(9):2478-87. DOI:10.1158/1535-7163.MCT-10-0321
[2] He Y, et al. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. Biochem Biophys Res Commun. 2014 Jul 4;449(3):344-50. DOI:10.1016/j.bbrc.2014.05.034
[3] Zhou E, et al. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Int Immunopharmacol. 2014 Sep;22(1):133-40. DOI:10.1016/j.intimp.2014.06.004
[4] Sa F, et al. Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett. 2015 Apr 23;593:7-12. DOI:10.1016/j.neulet.2015.03.016
[5] Zhang LQ, et al. Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways. J Ethnopharmacol. 2015 Apr 29. pii: S0378-8741(15)00306-2. DOI:10.1016/j.jep.2015.04.040